Related Experiment Video

Updated: Sep 27, 2025

Investigating Intestinal Inflammation in DSS-induced Model of IBD
08:43

Investigating Intestinal Inflammation in DSS-induced Model of IBD

Published on: February 1, 2012

67.7K

Administration of Aspergillus oryzae suppresses DSS-induced colitis

Ryo Nomura1, Sho Tsuzuki1, Takaaki Kojima2

  • 1Faculty of Agriculture, Meijo University, Nagoya, Aichi 468-8502, Japan.

Food Chemistry. Molecular Sciences
|April 13, 2022
PubMed

Insights

Administration of heat-killed Aspergillus oryzae spores increased beneficial gut bacteria and alleviated colitis in mice. This suggests A. oryzae has potential as a prebiotic for functional foods.

Area of Science:

  • Microbiology
  • Gastroenterology
  • Food Science

Background:

  • Aspergillus oryzae is a filamentous fungus traditionally used in Japanese fermented foods.
  • The impact of A. oryzae on the gut environment requires further investigation.

Purpose of the Study:

  • To investigate the effects of A. oryzae administration on the murine intestinal environment.
  • To evaluate the therapeutic potential of A. oryzae in dextran sodium sulfate-induced colitis.

Main Methods:

  • 16S rRNA gene sequencing was used to analyze gut microbiota composition.
  • Colitis was induced using dextran sodium sulfate in a mouse model.
  • Heat-killed A. oryzae spores and their cell wall components were administered.

Main Results:

  • Administration of heat-killed A. oryzae spores significantly increased the abundance of Bifidobacterium pseudolongum.
  • Both heat-killed A. oryzae spores and their cell wall components alleviated dextran sodium sulfate-induced colitis.
  • A. oryzae modulated the gut microbiota towards an anti-inflammatory profile.

Conclusions:

  • Aspergillus oryzae demonstrates prebiotic properties by enhancing beneficial gut bacteria.
  • A. oryzae and its components show therapeutic potential for inflammatory bowel diseases.
  • A. oryzae holds promise for developing functional foods with prebiotic benefits.
Keywords:
Aspergillus oryzaeBifidobacterium pseudolongumDSS, dextran sodium sulfateDSS-induced colitisGut microbiomeH&E, hematoxylin and eosinIBD, inflammatory bowel diseasePrebioticsTLC, thin-layer chromatography

More Related Videos

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation08:53

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

931
Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis08:58

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

12.4K

Related Concept Videos

Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
255
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
334
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
282
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
229
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents01:20

Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents

Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
346
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
215